Effect of 5-HT3 receptor antagonist (ondansetron) on functioning human pancreatic carcinoid cells

J. Ishizuka; A. C. Hsieh; C. M. Townsend; J. C. Thompson

doi:10.1016/0960-7404(93)90010-V

Effect of 5-HT₃ receptor antagonist (ondansetron) on functioning human pancreatic carcinoid cells

J. Ishizuka, A. C. Hsieh, C. M. Townsend, J. C. Thompson

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

5-Hydroxytryptamine (5-HT) is a mitogen for selected cell types. We have reported that 5-HT is an autocrine growth factor for functioning human pancreatic carcinoid (BON) cells; autocrine growth effect is transmitted by 5-HT_1A but not 5-HT_{1C 2} receptors, activation of which decreases cyclic AMP production through a pertussis toxin-sensitive inhibitory GTP-binding protein. In this study, the effect of 5-HT₃ receptor antagonist, ondansetron, on BON was examined. Ondansetron did not affect growth of BON cells and also affected neither stimulation of phosphatidylinositol hydrolysis or inhibition of cyclic AMP production evoked by 5-HT in BON cells. Ondansetron, however, inhibited mobilization of intracellular calcium evoked by 5-HT. Present findings suggest that BON cells possess 5-HT₃ receptors, but their roles in pancreatic carcinoid cells are still unknown.

Original language	English (US)
Pages (from-to)	221-225
Number of pages	5
Journal	Surgical oncology
Volume	2
Issue number	4
DOIs	https://doi.org/10.1016/0960-7404(93)90010-V
State	Published - Aug 1993
Externally published	Yes

Keywords

5-hydroxytryptamine
Ca
cAMP
carcinoid cells
ondansetron
phosphatidylinositol hydrolysis

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1016/0960-7404(93)90010-V

Cite this

@article{73beabf219c14e9b95c77750e8a71883,

title = "Effect of 5-HT3 receptor antagonist (ondansetron) on functioning human pancreatic carcinoid cells",

abstract = "5-Hydroxytryptamine (5-HT) is a mitogen for selected cell types. We have reported that 5-HT is an autocrine growth factor for functioning human pancreatic carcinoid (BON) cells; autocrine growth effect is transmitted by 5-HT1A but not 5-HT 1C 2 receptors, activation of which decreases cyclic AMP production through a pertussis toxin-sensitive inhibitory GTP-binding protein. In this study, the effect of 5-HT3 receptor antagonist, ondansetron, on BON was examined. Ondansetron did not affect growth of BON cells and also affected neither stimulation of phosphatidylinositol hydrolysis or inhibition of cyclic AMP production evoked by 5-HT in BON cells. Ondansetron, however, inhibited mobilization of intracellular calcium evoked by 5-HT. Present findings suggest that BON cells possess 5-HT3 receptors, but their roles in pancreatic carcinoid cells are still unknown.",

keywords = "5-hydroxytryptamine, Ca, cAMP, carcinoid cells, ondansetron, phosphatidylinositol hydrolysis",

author = "J. Ishizuka and Hsieh, {A. C.} and Townsend, {C. M.} and Thompson, {J. C.}",

note = "Funding Information: This work was supported by grants from the National Institutes of Health (NIH) (PO1 DK 35608, 5R37 DK 15241), the American Cancer Society (CB-571) and Glaxo, Inc. (SSA-R12). The authors would like to thank Jell Hsieh and Kirk Ives for their technical assistance and Bob Todd for his assistance in the preparation of this manuscript.",

year = "1993",

month = aug,

doi = "10.1016/0960-7404(93)90010-V",

language = "English (US)",

volume = "2",

pages = "221--225",

journal = "Surgical oncology",

issn = "0960-7404",

publisher = "Elsevier BV",

number = "4",

}

TY - JOUR

T1 - Effect of 5-HT3 receptor antagonist (ondansetron) on functioning human pancreatic carcinoid cells

AU - Ishizuka, J.

AU - Hsieh, A. C.

AU - Townsend, C. M.

AU - Thompson, J. C.

N1 - Funding Information: This work was supported by grants from the National Institutes of Health (NIH) (PO1 DK 35608, 5R37 DK 15241), the American Cancer Society (CB-571) and Glaxo, Inc. (SSA-R12). The authors would like to thank Jell Hsieh and Kirk Ives for their technical assistance and Bob Todd for his assistance in the preparation of this manuscript.

PY - 1993/8

Y1 - 1993/8

N2 - 5-Hydroxytryptamine (5-HT) is a mitogen for selected cell types. We have reported that 5-HT is an autocrine growth factor for functioning human pancreatic carcinoid (BON) cells; autocrine growth effect is transmitted by 5-HT1A but not 5-HT 1C 2 receptors, activation of which decreases cyclic AMP production through a pertussis toxin-sensitive inhibitory GTP-binding protein. In this study, the effect of 5-HT3 receptor antagonist, ondansetron, on BON was examined. Ondansetron did not affect growth of BON cells and also affected neither stimulation of phosphatidylinositol hydrolysis or inhibition of cyclic AMP production evoked by 5-HT in BON cells. Ondansetron, however, inhibited mobilization of intracellular calcium evoked by 5-HT. Present findings suggest that BON cells possess 5-HT3 receptors, but their roles in pancreatic carcinoid cells are still unknown.

AB - 5-Hydroxytryptamine (5-HT) is a mitogen for selected cell types. We have reported that 5-HT is an autocrine growth factor for functioning human pancreatic carcinoid (BON) cells; autocrine growth effect is transmitted by 5-HT1A but not 5-HT 1C 2 receptors, activation of which decreases cyclic AMP production through a pertussis toxin-sensitive inhibitory GTP-binding protein. In this study, the effect of 5-HT3 receptor antagonist, ondansetron, on BON was examined. Ondansetron did not affect growth of BON cells and also affected neither stimulation of phosphatidylinositol hydrolysis or inhibition of cyclic AMP production evoked by 5-HT in BON cells. Ondansetron, however, inhibited mobilization of intracellular calcium evoked by 5-HT. Present findings suggest that BON cells possess 5-HT3 receptors, but their roles in pancreatic carcinoid cells are still unknown.

KW - 5-hydroxytryptamine

KW - Ca

KW - cAMP

KW - carcinoid cells

KW - ondansetron

KW - phosphatidylinositol hydrolysis

UR - http://www.scopus.com/inward/record.url?scp=0027330208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027330208&partnerID=8YFLogxK

U2 - 10.1016/0960-7404(93)90010-V

DO - 10.1016/0960-7404(93)90010-V

M3 - Article

C2 - 8252212

AN - SCOPUS:0027330208

SN - 0960-7404

VL - 2

SP - 221

EP - 225

JO - Surgical oncology

JF - Surgical oncology

IS - 4

ER -